1. Scrip
  2. >>Business
  3. >>Strategy

Merck Solidifies RCC Position, While Bristol Gets Good SubQ Readout

 
• By Joseph Haas

Keytruda becomes the first immuno-oncology agent to show an overall survival benefit in adjuvant renal cell carcinoma. Bristol gains ground on Merck and Roche in race to develop a subcutaneous checkpoint inhibitor.

Merck_New_Jersey
Merck demonstrates an overall survival benefit with Keytruda in RCC

Merck & Co., Inc. is reinforcing its strength in renal cell carcinoma with data showing an overall survival benefit from the study that earned Keytruda approval in 2021 for adjuvant treatment of clear cell renal cell carcinoma in patients at intermediate-high or high risk of recurrence, but Bristol Myers Squibb Company reported data that same day for its subcutaneous formulation of Opdivo showing non-inferiority to the intravenously infused version now in use.

Key Takeaways

  • Keytruda demonstrates overall survival benefit in post-surgical RCC patients at risk of recurrence.

  • The company hopes to get the Phase III data added to...

Both companies released the datasets 27 January at the American Society of Clinical Oncology’s 2024 Genitourinary Cancers Symposium. But while Merck’s data appeared to further shut the door on BMS...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.